Form 4 for LYEL Lyell Immunopharma, Inc.
Accepted 2025-08-22 00:00:00 ET · period of report 2025-08-20 · accession 0001415889-25-022746 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-08-22 | 2025-08-21 | LYEL | Hill Stephen J. | COO | S - Sale | $10.54 | -1,004 | 15.8K | -6% | -$10.6K | |
| 2025-08-22 | 2025-08-20 | LYEL | Hill Stephen J. | COO | A - Grant | $0.00 | +8,000 | 16.8K | +90% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-08-21 | S | D | 1,004 | $10.54 | 15,845 | D | — | — | (F2) Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units. (F3) The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.49 to $10.64 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. |
| 2 | Common | Common Stock | 2025-08-20 | A | A | 8,000 | $0.00 | 16,849 | D | — | — | (F1) Pursuant to performance-based restricted stock units granted to the reporting person on February 9, 2024, 4,000 shares were issued on the Transaction Date upon the achievement of certain performance criteria certified by the compensation committee of the Issuer's board of directors on the Transaction Date and 4,000 shares will be issued on August 20, 2026, subject to the reporting person providing service through such date. |